Novel Digital Application for Patients With Acute Leukemia

Description

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.

Conditions

Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.

Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia

Novel Digital Application for Patients With Acute Leukemia

Condition
Relapsed Adult Acute Myeloid Leukemia
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital (MGH), Boston, Massachusetts, United States, 02114

Durham

Duke University, Durham, North Carolina, United States, 27710

Seattle

Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Hospitalized patients (age \> 18 years) with a diagnosis of AML.
  • * Initiating treatment with either intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen that typically requires a prolonged 3-6-week hospitalization and/or recovery.
  • * Ability to comprehend and speak English as the digital apps are only available in English
  • * Patients with a diagnosis of acute promyelocytic leukemia
  • * Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.

Ages Eligible for Study

18 Years to 120 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Study Record Dates

2030-04-30